Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Osteoporosis
Interventions: DRUG: risedronate sodium|OTHER: diagnostic laboratory biomarker analysis
Sponsor: ETOP IBCSG Partners Foundation